

PainChek expands Australian market reach with BESTMED reseller agreement

PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart-based pain assessment and monitoring application, is pleased to announce a new reseller agreement with leading Australian medication management provider Best Health Solutions Pty Ltd (BESTMED).

BESTMED is a market leader for medication management in the Australian residential aged care sector and has also expanded into the home care sector.

This reseller agreement is effective immediately and will see BESTMED offer the PainChek® digital pain assessment solution across its existing customer network, expanding PainChek®'s reach in the residential aged care market and broadening access to innovative pain management technology.

This partnership will focus on facilitating sales, enhancing pain management practices for care providers and the people they care for.

PainChek®'s unique assessment technology combines Al-driven pain scoring with the Numerical Rating Scale (NRS), enabling a comprehensive, real-time evaluation of pain levels. The partnership with BESTMED aims to support streamlined adoption of this technology, helping facilities and carers improve resident outcomes, reduce distress, and provide better-quality care.

PainChek® CEO and Managing Director Philip Daffas commented: "We are excited to partner with BESTMED and expand the reach of PainChek®'s innovative pain assessment technology. This agreement aligns with our strategy to further penetrate the aged care market and grow our presence across new care settings, building on our commitment to revolutionize pain management with accessible, AI-driven solutions."

BESTMED's CEO Phil Offer said: "The BESTMED medication system is used in over 1,100 homes supporting more than 100,000 Australians every day. We're proud to extend our relationship with PainChek® that builds on our existing integration offering in market. It demonstrates our commitment to partnering with leading innovators to produce better outcomes for our joint clients in residential and home care."

This agreement represents a significant opportunity for PainChek® to broaden its market impact, working with BESTMED and their established client relationships.

The Company is unable to provide an estimate for the revenue generated from this agreement and commercial progress on the partnership will be reported in PainChek's future quarterly updates. This announcement has been authorized for release by PainChek CEO Philip Daffas.

For more information:

Natalie Climo Philip Daffas Company Secretary, PainChek CEO, PainChek natalie.climo@boardroomlimited.com.au

philip.daffas@painchek.com

02 8016 2875 0406 537 235

About PainChek®

<u>PainChek</u>* is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,600 aged care facilities, with more than 7,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the <u>Journal of Alzheimer's Disease</u>. An article in <u>BMC Geriatrics</u> indicates that PainChek[®] is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found <u>here</u>.

PainChek has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated PainChek Infant app identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: https://painchek.com

About BESTMED:

Safer, easier, better medication management

BESTMED provides a complete medication management solution connecting medication prescribing, dispensing and administration to a single resident medication record. Cloud-based, real-time and transcription-free, BESTMED is an industry leader in developing systems for pharmacy, aged care, home care and clinicians to improve safety, efficiencies and reporting to meet aged care requirements. All users on the BESTMED network benefit from intelligent automated workflows that significantly reduce the errors that arise from manual processing and gain exceptional operational efficiency.

BESTMED continues to invest significantly in research and development to eradicate medication errors and is working on next-generation solutions in partnership with leading university researchers.

For more information, visit: https://BESTMED.au/